(PRWEB) October 22, 2012
Shire, a global specialty biopharmaceutical company, is pleased to announce that it has launched its 2013 ADHD Scholarship Program. The program is for individuals in the United States diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) who are pursuing higher education at a college, vocational school or technical school. Since the start of the program in 2011, Shire has announced 75 national scholarship award recipients and 10 employee award recipients. To see a full list of scholarship recipients, visit http://www.ShireADHDscholarship.com.
The Shire ADHD Scholarship includes a $2,000 monetary award and offers a prepaid year of ADHD coaching services. The ADHD coaching services are provided by the Edge Foundation and are intended to assist the scholarship recipient with the transition to higher education. Fifty one-time scholarships will be awarded in June 2013. The deadline to apply is March 27, 2013. For information on eligibility requirements, the scholarship application process and more, visit http://www.ShireADHDscholarship.com.
The scholarship program has already made an impact on past recipients and their families. Karen Peterson, the parent of a 2011 scholarship recipient, said, “I am thankful that Shire offers a scholarship and coaching services to help my child pursue higher education.”
“This scholarship allows Shire to continue to recognize and support the individuals who work hard to overcome the challenges of ADHD, and help them continue their educational pursuits,” said Mike Yasick, Senior Vice President of Shire’s Behavioral Health Business Unit.
The Shire ADHD Scholarship also includes weekly sessions with an ADHD coach from the Edge Foundation. In addition to weekly coaching sessions, ADHD coaches offer support to students via e -mail and phone to help students meet their goals. This support may be important for students transitioning to the higher education environment because they have more free time and less adult supervision.
Robert Tudisco, Executive Director of the Edge Foundation, said, “At Edge we are proud to be a part of Shire’s genuine commitment to these students. Any scholarship offers access to higher education, but this program is unique in that it offers not just access but the support that these students need.”
The Edge Foundation is a Seattle-based nonprofit organization that offers support for students with ADHD. The Edge Foundation’s primary mission is to provide access to qualified, professional coaches for students with ADHD as part of their multimodal treatment program. For more information about the Edge Foundation, visit http://www.edgefoundation.org.
Shire’s ADHD Scholarship Program is part of Shire’s patient centric approach that provides support to ADHD patients and their caregivers.
For further information, please contact:
Media Gwen Fisher (gfisher (at) shire (dot) com) 1-484-595-9836
Charlotte Zang (czang (at) benchworks (dot) com) 1-410-810-8862
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company’s website: http://www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
©2012 Shire US Inc., Wayne, PA 19087